ArticleMedicine2026
Recurrent giant retroperitoneal liposarcoma: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
rationaleThis report describes an exceptionally large recurrent tumor with a long-standing and recurrent clinical course, thereby adding to the limited literature on giant myxoid liposarcoma. PATIENT CONCERNS: A 48-year-old male with a 13-year history of recurrent liposarcoma presented with progressive abdominal distension and marked abdominal enlargement over 4 months. Imaging demonstrated a massive abdominopelvic mass measuring 352 mm in maximum diameter. DIAGNOSES: Histopathological examinations from multiple prior resections had consistently confirmed recurrent myxoid liposarcoma.
interventionsDuring the current admission, the patient underwent complete resection of a giant retroperitoneal tumor, with pathology again verifying myxoid liposarcoma. No adjuvant chemotherapy or radiotherapy was administered. OUTCOMES: At 18-month follow-up, the patient developed multiple abdominopelvic metastases, indicating the aggressive biological behavior and high recurrence risk of retroperitoneal myxoid liposarcoma. LESSONS: This case describes an exceptionally large recurrent retroperitoneal liposarcoma measuring 43 × 32 × 23 cm and weighing approximately 20 kg, with a prolonged 13-year clinical course characterized by multiple recurrences and repeated surgical resections. It demonstrates that even an extremely large recurrent tumor may remain amenable to surgical resection following comprehensive imaging evaluation and multidisciplinary planning, with appropriate preparation for possible adjacent-organ resection. Nevertheless, the development of multifocal abdominopelvic recurrence 18 months after surgery underscores the persistent risk of recurrence and the need for structured, long-term postoperative surveillance. This case contributes to the limited literature by illustrating both the feasibility and the inherent limitations of repeated surgical management for giant recurrent retroperitoneal liposarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.